Signal12 Pharmaceuticals has aligned with the FDA on its phase 3 clinical trial strategy for Pro-ocular, a novel drop-free ...

Results also showed significant improvements in corneal staining and tear production, with effects observed as early as week 4 and maintained through week 12. Patients reported reduced reliance on ...

The topical treatment had no significant effect on total or central corneal fluorescence staining score.